Oncology

Latest News

Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC

Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC

By Alana Hippensteele, MA

September 7th 2025

Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.

Microscopic view of non small cell lung cancer cells. Image Credit: © Keopaserth - stock.adobe.com

From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC

By Alana Hippensteele, MA

September 6th 2025

Lung cancer. Image Credit: © Dr Microbe - stock.adobe.com

Comparing Global Standards in Lung Cancer: NCCN, ESMO, and CHEST Guidelines

By Alana Hippensteele, MA

September 6th 2025

Most of the patients who experienced superior outcomes with atezolizumab and chemotherapy had higher levels of NOTCH1 expression. | Image credit: Pixel-Shot - stock.adobe.com

NOTCH1 Levels Impact Immune Response in SCLC

By Jared Kaltwasser

September 2nd 2025

The findings can help guide ongoing and future clinical trials to help solve remaining challenges in LS-SCLC. | Image credit: Jennifer - stock.adobe

Neoadjuvant Immunotherapy Plus Chemotherapy Shows Promise in LS-SCLC

By Jared Kaltwasser

August 31st 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

September 8th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

September 8th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

December 16th 2016

CMS Decision to Abandon Medicare Part B Demo Greeted With Sighs of Relief

Christina Mattina

After widespread criticism from healthcare providers, drug companies, and lawmakers, CMS has announced that it will not go forward with its proposed Medicare Part B payment program. The experimental reimbursement model was intended to reduce outpatient drug spending, but oncologists worried it would have unfairly slashed their Part B payments.

This Week in Managed Care: December 16, 2016

December 16th 2016

This Week in Managed Care: December 16, 2016

This week, the top stories in managed care include President Barack Obama signing the 21st Century Cures Act into law, findings from the CDC that opioid abuse has reduced life expectancy for Americans, and CVS announced a new program to lower costs for patients with diabetes.

December 16th 2016

Craig Sager Loses His Fight Against AML

Surabhi Dangi-Garimella, PhD Mary Caffrey

Craig Sager, a sideline reporter for CNN and Turner Sports, has died a little over 2 and a half years after being diagnosed with acute myeloid leukemia (AML).

December 15th 2016

Strategies for OCM Implementation at the COA Payer Summit

Surabhi Dangi-Garimella, PhD

At the Community Oncology Alliance (COA) Payer Exchange Summit V, panelists provided insights for successful implementation of payment models in oncology clinics.

December 15th 2016

How Can Practices Seek Success With Oncology Payment Reform?

Surabhi Dangi-Garimella, PhD

Bruce Gould, MD, president and medical director, Northwest Georgia Oncology Center, and president of the Community Oncology Alliance, presented an overview of how cancer care has improved over the years and what the current challenges are.

Jonathan Hirsch: How Syapse Uses Health IT to Implement Precision Medicine

December 15th 2016

Jonathan Hirsch: How Syapse Uses Health IT to Implement Precision Medicine

Implementing precision medicine is a complex undertaking that cannot be accomplished without the use of health IT tools, according to Jonathan Hirsch, founder and president of Syapse. He identified the 4 key functions of healthcare IT that allow Syapse to expand access to precision medicine.

December 15th 2016

Second Scalp Cooling Device to Prevent Chemotherapy-Induced Alopecia Seeks FDA Approval

Surabhi Dangi-Garimella, PhD

Paxman is seeking approval for using its scalp cooling device as an intervention to prevent chemotherapy-induced alopecia (CIA) in women undergoing chemotherapy treatment for breast cancer.

December 14th 2016

NIH-Funded Survey Reports Decline in Vaping and Use of Hookahs, Cigarettes by Teens

Surabhi Dangi-Garimella, PhD

A survey funded by the National Institutes of Health (NIH)’s National Institute on Drug Abuse has found that vaping, cigarette smoking, and use of hookahs among adolescents has declined over the past year.

December 14th 2016

Preventing Chemotherapy-Associated Alopecia: A Case for Palliation?

Surabhi Dangi-Garimella, PhD

Chemotherapy-associated alopecia, which drastically changes how a person looks and feels, can significantly impact the patient’s quality of life, over and above the physical exhaustion associated with their treatment. Raising awareness among providers, patients, and their caregivers can help.

December 13th 2016

Palliative Care for Patients With Advanced Illness: A Changing Policy Landscape

A lag in policy changes has resulted in significant variation across palliative care programs for treating advanced illnesses. A recent shift in policy has, however, allowed small-scale testing of community-based palliative care delivery and some innovations in other delivery systems.

December 13th 2016

FDA Reaffirms Bladder Cancer Risk With Use of Pioglitazone

Surabhi Dangi-Garimella, PhD

The FDA has released an updated safety announcement following a fresh review of data on the type 2 diabetes treatment pioglitazon to confirm that the drug may increase a person’s likelihood of developing bladder cancer.

December 13th 2016

Step Therapy Cost-Effective for Psychological Distress in Patients With Cancer

A study published in the Journal of Clinical Oncology has found that step therapy can be cost-effective in patients with cancer who are under psychological duress.

Barry Russo on Quality Measures Data and Value Frameworks

December 13th 2016

Barry Russo on Quality Measures Data and Value Frameworks

Barry Russo, CEO of The Center for Cancer & Blood Disorders, said that his practice continues to collect quality and claims data from a number of sources, even though it isn’t easy. Russo also said that payers are not particularly interested in participating in a value framework, instead choosing to focus on the oncology care model (OCM).

December 12th 2016

Social Ties Significantly Impact Survival of Patients With Breast Cancer

Surabhi Dangi-Garimella, PhD

An exhaustive study conducted by researchers at the Kaiser Permanente Division of Research has found that a woman’s social network can significantly affect her chances of survival following breast cancer.

December 12th 2016

Achieving Value Through Palliative Care

Allison Silvers, MBA Stacie Sinclair, MPP Diane E. Meier, MD, FACP

Palliative care is an underutilized and powerful resource in the drive towards value. In the current article, we review published evidence and highlight how Medicare Advantage plans, accountable care organizations, and oncology practices can benefit from concurrent palliative care under value-based payments.

December 9th 2016

Smoking Cessation Programs Need a Boost Under Medicaid Expansion

Surabhi Dangi-Garimella, PhD

The CDC's Morbidity and Mortality Weekly Report recommends that Medicaid expansion states should direct more attention to smoking cessation programs to improve access and raise awareness about these programs among beneficiaries and providers.

December 9th 2016

Welcome to the Future: Telemedicine and Value-Based Payment

Michael D. Fratkin, MD Stephen G. Franey, MBA

By using telemedicine and relocating the center of care to where a person lives, we have an opportunity to address more unmet demand for palliative care, while giving more control to the seriously ill to meet their stated needs.

This Week in Managed Care: December 9, 2016

December 9th 2016

This Week in Managed Care: December 9, 2016

This week, the top stories in managed care included poll results that show growing numbers of Republicans want the Affordable Care Act scaled back instead of repealed, Jardiance received a new indication for patients with type 2 diabetes, and CareMore reported care coordination gaps for seniors.

December 8th 2016

Researchers Develop Model to Predict Chemotherapy Success in Aggressive Breast Cancer

Christina Mattina

At the 2016 San Antonio Breast Cancer Symposium, researchers announced the creation of a model to identify patients with triple negative breast cancer who are most likely to respond to chemotherapy.

December 8th 2016

Integrating Palliative Care Into Outpatient Oncology: A Case Study

Karen Mulvihill, DNP, APRN, FNP-BC, ACHPN

This article examines the integration of palliative care in a community cancer center-an example of how one program integrated palliative care.

December 7th 2016

ASCO Makes Recommendations to Reduce Cardiac Risk in Survivors of Adult-Onset Cancers

Surabhi Dangi-Garimella, PhD

A panel of 21 expert clinicians from the field conducted a systematic review of meta-analyses randomized clinical trials, observational studies, and clinical experience, to develop recommendations that have been published in the Journal of Clinical Oncology.

December 6th 2016

CAR T-Cells of Defined Composition Effective in Ibrutinib-Refractory CLL

Surabhi Dangi-Garimella, PhD

In high-risk patients with chronic lymphocytic leukemia (CLL), CD19 chimeric antigen receptor (CAR) T-cells of defined composition can be administered with an acceptable early toxicity.

December 5th 2016

Innovative Approach to Precision Trial Design: NCI-MATCH and Beat AML

Surabhi Dangi-Garimella, PhD

Representatives from the Beat acute myeloid leukemia (AML) and National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH), which incorporate genomic profiling to assign patients to different treatment arms, provided an insight on trial design and a progress report.

Dr Robert Carlson Discusses Future of Immuno-Oncology, Importance of Patient Advocacy

December 5th 2016

Dr Robert Carlson Discusses Future of Immuno-Oncology, Importance of Patient Advocacy

Immuno-oncology will be an important part of cancer care in the future, but probably not the only part, predicted Robert W. Carlson, MD, CEO of the National Comprehensive Cancer Network. He also explained how patient advocacy and an enduring healthcare system are essential to the advancement of cancer care.

December 5th 2016

RESONATE-2 Continues to Impress With Single-Agent Ibrutinib for CLL/SLL at 29 Months

Surabhi Dangi-Garimella, PhD

Older patients diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) continue to present a favorable response to single-agent ibrutinib, at a follow-up of 29 months, in phase 3 of the RESONATE-2 trial.

Pam Mangat Explains How ASCO Works to Educate Oncologists on Precision Medicine

December 5th 2016

Pam Mangat Explains How ASCO Works to Educate Oncologists on Precision Medicine

Pam Mangat, MS, associate director TAPUR study at the American Society of Clinical Oncology, says that the organization has developed a number of initiatives to educate oncology practitioners on the potential of precision medicine, such as testing guidelines, online courses, a virtual tumor board, and clinical trials.

December 4th 2016

ASH Symposium on Quality Addresses Health IT Challenges for the Provider and the Patient

Surabhi Dangi-Garimella, PhD

The Special Symposium on Quality at the 58th American Society of Hematology Annual Meeting & Exposition, looked at how health information technology can be utilized to improve healthcare quality, enhance patient-provider shared decision-making, and facilitate efforts in quality research.

December 4th 2016

Phase 3 LyMa Trial: Rituximab After ASCT Improves OS in Mantle Cell Lymphoma

Surabhi Dangi-Garimella, PhD

Phase 3 results from the LyMa trial show that rituximab maintenance therapy after autologous stem cell transplant (ASCT) prolongs event-free survival, progression-free survival, and overall survival (OS) in previously untreated young patients with mantle cell lymphoma (MCL).

Dr Carrie Stricker Discusses IT Solutions That Engage Both Cancer Patients and Care Teams

December 4th 2016

Dr Carrie Stricker Discusses IT Solutions That Engage Both Cancer Patients and Care Teams

Innovative health IT tools like those developed by Carevive help maximize the balance between patient self-management and care team engagement, which is especially important in the era of value-based care, according to Carrie Stricker, PhD, RN, AOCN, chief clinical officer and co-founder of Carevive.

Dr Joseph Alvarnas on How Comorbidities Impact Care Decisions for Cancer Patients

December 4th 2016

Dr Joseph Alvarnas on How Comorbidities Impact Care Decisions for Cancer Patients

A cancer patient’s comorbid diseases have important implications for setting goals and selecting treatment, said Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology. Clinicians must keep comorbidities in mind as they base oncology care upon that person as an individual.

...

88 89 90 91 92 93 94 95 96

...

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions